JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 6, 2006; DOI: 10.1124/jpet.106.104315


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.104315v1
318/3/1178    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gass, J.
Right arrow Articles by Khosla, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gass, J.
Right arrow Articles by Khosla, C.


Received for publication March 14, 2006.
Revised June 1, 2006.
Accepted for publication June 2, 2006.

Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat

Jonathan Gass 1, Harmit Vora 1, Michael T Bethune 1, Gary M Gray 1, Chaitan Khosla 1*

1 Stanford University

* Address correspondence to: E-mail: khosla{at}stanford.edu

Abstract

Celiac Sprue is a multi-factorial disease characterized by an intestinal inflammatory response to ingested gluten. Proteolytically resistant gluten peptides from wheat, rye and barley persist in the intestinal lumen, and elicit an immune response in genetically susceptible individuals. Here we demonstrate the in vivo ability of a gluten-digesting protease ("glutenase") to accelerate the breakdown of a gluten-rich solid meal. The proenzyme form of endoprotease B, isoform 2 from Hordeum vulgare (EP-B2) was orally administered to adult rats with a solid meal containing 1 g gluten. Gluten digestion in the stomach and small intestine was monitored as a function of enzyme dose and time by HPLC and mass spectrometry. In the absence of supplementary EP-B2, gluten was solubilized and proteolyzed to a limited extent in the stomach, and was hydrolyzed and assimilated mostly in the small intestine. In contrast, EP-B2 was remarkably effective at digesting gluten in the rat stomach in a dose and time dependent fashion. At a 1:25 EP-B2:gluten dose, the gastric concentration of the highly immunogenic 33-mer gliadin peptide reduced by more than 50-fold within 90 min, with no overt signs of toxicity. Evaluation of EP-B2 as an adjunct to diet control is therefore warranted in celiac patients.


Key words: 33-mer, barley endoprotease EP-B2, celiac sprue, gliadin, gluten, glutenase


This article has been cited by other articles:


Home page
GutHome page
N. Cerf-Bensussan, T. Matysiak-Budnik, C. Cellier, and M. Heyman
Oral proteases: a new approach to managing coeliac disease
Gut, February 1, 2007; 56(2): 157 - 160.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.